Cardiol Therapeutics Inc. Class A

As of June 30, 2026, Cardiol Therapeutics Inc. Class A carries a market capitalization of 171.76M, placing it among publicly traded companies globally. Its enterprise value stands at 145.78M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cardiol Therapeutics Inc. Class A's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Cardiol Therapeutics Inc. Class A has 115.27M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Cardiol Therapeutics Inc. Class A maintains a current ratio of 5.55, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Cardiol Therapeutics Inc. Class A posted a negative return on equity (ROE) of -190.18, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -138.26, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 22.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Cardiol Therapeutics Inc. Class A's stock has declined approximately 1.80% over the past 52 weeks. The 50-day moving average sits at 2.40, while the 200-day moving average is 1.81.

Over the twelve months ended June 30, 2026, Cardiol Therapeutics Inc. Class A generated - - in revenue and converted that into -34.08M in net income, yielding earnings per share of -0.33. EBITDA reached -35.77M, while operating income came in at -35.86M.

As of June 30, 2026, Cardiol Therapeutics Inc. Class A holds 26.08M in cash and equivalents against 106,998.00 in total debt, resulting in a net debt position of -26.08M. Total book value stands at 24.03M, with working capital of 23.96M providing operational flexibility.

Cardiol Therapeutics Inc. Class A produced -24.05M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -56,720.00 in capital expenditures, free cash flow totaled -24.10M - equivalent to -0.24 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -15.82: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -18.40, meaning Cardiol Therapeutics Inc. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Cardiol Therapeutics Inc. Class A has an Altman Z-Score of 5.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.